{
  "docId": "019de074-7a94-707c-b002-278357aaec02",
  "docSlug": "fb2ab974265a0e95c40d5a8a75128cd1",
  "documentTitle": "BenevolentAI | Results Presentation Deck | 38 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 38,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "ceo_quote",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-7a94-707c-b002-278357aaec02/23",
  "deckHref": "/decks/019de074-7a94-707c-b002-278357aaec02",
  "deckJsonHref": "/decks/019de074-7a94-707c-b002-278357aaec02.json",
  "deckAnchorHref": "/decks/019de074-7a94-707c-b002-278357aaec02#slide-23",
  "components": [
    {
      "bbox": {
        "x": 0.95,
        "y": 0.9
      },
      "kind": "list",
      "text": "BEN-2293: Top-line results of the Phase IIa clinical trial expected in Q1 2023; Out-license in H2 2023 subject to results. BEN-8744: Initiate the Phase I study in H1 2023. BEN-28010: Submit the CTA in H2 2023. 2023: Continued investment, commercial collaboration, IND-enabling studies, progress pipeline.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f5486bab-2926-49ee-bde2-b052cedde074",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.4,
        "y": 0.7
      },
      "kind": "quote",
      "text": "With the world's attention on AI applications that deliver real- world impact, we are strongly positioned to capitalise on this moment. With our substantial portfolio of platform-generated drugs, our work with big pharma and research collaborators, and our continued investment in state-of-the-art technology, we are showing every day how AI can be used to unlock the next wave of biopharma innovation.",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d7f2b44-84b5-467f-b7c8-5591a3b014ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "x": 0.95,
        "y": 0.15
      },
      "kind": "title",
      "text": "Poised for growth: multiple value inflection points expected",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abc74cb2-b161-48c8-bf2d-81666a02083b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Action Titles",
      "slug": "action-titles",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "4ce055de-5f0f-4b69-96b5-d4fc5a1b8aa2",
      "evidence": "Poised for growth: multiple value inflection points expected",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}